VTK-231

VTK-231 is a preclinical-stage targeted protein degrader (TPD) developed by Vitarka Therapeutics in collaboration with an undisclosed pharmaceutical partner. The drug is designed as a Pan-MEK degrader, targeting the mitogen-activated protein kinase kinase (MEK) family to achieve broad suppression of the MAPK signaling cascade. Unlike traditional inhibitors, VTK-231 utilizes the cell's protein degradation machinery to eliminate MEK proteins, thereby inhibiting downstream signaling through the ERK, JNK, and p38 pathways. This comprehensive inhibition is intended to treat solid tumors that are driven by dysregulation in these specific MAPK branches. VTK-231 is administered systemically and is currently undergoing preclinical efficacy studies.